Skip to main content
Premium Trial:

Request an Annual Quote

Aaron J. Sender, Bernadette Toner, Jennifer Friedlin

Premium

Aaron J. Sender, (“Happy Days at the HAP Factory,” p. 26), was torn between the worlds of science and writing before realizing he could be citizen of both. After graduate training in both biology and journalism at New York University and experience at The Sciences and Discover, he reported for GenomeWeb.com and BioInform before joining the staff of Genome Technology as senior writer. Lately, he’s been trying to save up some cash for a high-throughput sequencer to use at parties.

She’s been a hostess in a Las Vegas wedding chapel and kept the books for a strawberry farm in Oregon, but Bernadette Toner (“Matchmaking for Genomes, Automated,” p. 24) says she’ll stick with science and technology journalism for a while. Now managing editor of BioInform, Bernadette most recently covered emerging technology for Inside R&D, where she wrote about a range of topics, from nanotechnology to civil engineering. “Science writing really appeals to me because it’s one of the few jobs where you’re always learning something new and interesting,” she says. And it sure beats scheduling Elvis impersonators to sing at people’s weddings.

Jennifer Friedlin (“Knocked out by Nasdaq,” p. 48) is managing editor, news, for GenomeWeb.com. Before joining the company in July, she worked for a joint venture between TheStreet.com and The New York Times online. She has also covered business for The Jerusalem Post and Reuters in Jerusalem. Despite having resided in the world’s political hotbed for 4 years, Jennifer says, “Nothing beats the excitement of covering a young and growing industry like genomics.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.